NEWS & EVENTS
Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)

Shattuck Labs Press Release May 6, 2019  

Read more
Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology

Press Release 2017

Read more
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Fromm et.al Journal for ImmunoTherapy of Cancer, 18 December 2018

Read more
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (PD1-Fc-OX40L), for Cancer Immunotherapy

SITC 2018

Read more
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (SIRPĪ±-Fc-CD40L), for Cancer Immunotherapy

SITC 2018

Read more
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for Cancer Immunotherapy

SITC 2018

Read more